Abstract
Africa is the main birthplace of sickle mutations; the number of newborns affected by sickle cell disease is estimated at 200,000 per year. However, because of low family income and public health funding and, to a lesser extent, because of local beliefs about sickle cell disease, overall treatment of patients is still poor and, in some places, inadequate. Efforts to adapt therapeutic options and overcome difficulties are presented and analyzed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
